Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2014 May 12;25(5):560-2. doi: 10.1016/j.ccr.2014.04.019.

Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.

Author information

1
Mount Sinai Liver Cancer Program, Division of Liver Diseases, ICAHN School of Medicine at Mount Sinai, New York, NY 10029, USA; HCC Translational Research Lab, BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona. Barcelona 08036, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona 08036, Catalonia, Spain. Electronic address: josep.llovet@mssm.edu.

Abstract

Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.

PMID:
24823635
PMCID:
PMC4071286
DOI:
10.1016/j.ccr.2014.04.019
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center